Cellebrite DI Ltd. reported second-quarter revenue below expectations and lowered its full-year guidance due to delays caused by foreign permit requirements. The company also announced an immediate CEO replacement, with Shiv Ramji taking over from Tom Hogan. Following these developments, Cellebrite's stock price dropped 29%. Kaplan Fox & Kilsheimer LLP has launched an investigation into potential securities violations related to these events, inviting affected investors to come forward.
Viking Holdings reported better-than-expected Q2 earnings with revenue up 16.5% to $2.19 billion and EPS of $1.31, beating estimates. The growth was driven by adding seven river and two ocean vessels, increasing passenger cruise days by 10.9%. Howeve...
Belden, Inc. reported a record second-quarter revenue of $750.20 million, driven by its role as a key supplier in AI infrastructure. Analysts raised the price target to $170, suggesting a potential 31.68% upside from the current price of around $129....
Director Carande has purchased 2,101 shares of United Community Banks. This insider buying may indicate confidence in the company's future prospects. Investors often view such transactions as a positive signal, potentially influencing market sentimen...
Bio-Techne reported Q4 revenues of $321.2 million, slightly surpassing estimates, but its adjusted EPS fell 1.9% year-over-year to $0.52, showing mixed financial results. The company's stock remains close to Merck KGaA's $73 per share acquisition off...
Estée Lauder reported quarterly earnings per share of $0.39, surpassing analyst estimates of $0.32, and revenue of $3.62 billion, exceeding expectations. The company showed 5% organic sales growth for the fourth consecutive quarter and raised its ful...
